MeSH term
Frequency | Condition_Probility | Aged | 56 | 0.0 |
Humans | 823 | 0.0 |
Risk | 2 | 0.0 |
Time Factors | 40 | 0.0 |
Adult | 128 | 0.0 |
Child | 20 | 0.0 |
Female | 244 | 0.0 |
Male | 130 | 0.0 |
Aged, 80 and over | 12 | 0.0 |
English Abstract | 39 | 0.0 |
Middle Aged | 80 | 0.0 |
Cell Movement | 4 | 0.0 |
Infant, Newborn | 12 | 0.0 |
Embryo Implantation/*physiology | 12 | 32.0 |
Endometrium/*metabolism | 9 | 10.0 |
Gene Expression Regulation/*physiology | 5 | 1.0 |
Menstrual Cycle/metabolism | 2 | 9.0 |
Research Support, Non-U.S. Gov't | 482 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 187 | 0.0 |
Animals | 350 | 0.0 |
Cells, Cultured | 151 | 0.0 |
RNA, Messenger/biosynthesis | 14 | 0.0 |
Rabbits | 8 | 0.0 |
Antibodies, Monoclonal/pharmacology | 8 | 1.0 |
*Bone Resorption | 2 | 10.0 |
Calcium/metabolism | 4 | 0.0 |
Cytokines/metabolism/*pharmacology | 3 | 33.0 |
Growth Inhibitors/pharmacology | 35 | 23.0 |
Lymphokines/pharmacology | 33 | 18.0 |
Peptides/pharmacology | 15 | 7.0 |
Rats | 51 | 0.0 |
Rats, Wistar | 6 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 37 | 0.0 |
Acute-Phase Proteins/metabolism | 6 | 9.0 |
Amino Acid Sequence | 54 | 0.0 |
Apoptosis | 6 | 0.0 |
Base Sequence | 78 | 0.0 |
Cell Death | 2 | 0.0 |
Cytokines/genetics | 5 | 4.0 |
DNA Primers | 16 | 0.0 |
DNA-Binding Proteins/*metabolism | 12 | 0.0 |
Molecular Sequence Data | 100 | 0.0 |
Neoplasm Staging | 3 | 0.0 |
Peptides/*genetics | 6 | 6.0 |
Phosphotyrosine/analysis | 2 | 3.0 |
Receptors, Cytokine/*genetics | 7 | 12.0 |
Reverse Transcriptase Polymerase Chain Reaction | 26 | 0.0 |
Trans-Activators/*metabolism | 10 | 1.0 |
Transcription, Genetic | 19 | 0.0 |
Tumor Cells, Cultured | 97 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Calcium Sulfate | 3 | 75.0 |
Dysprosium | 2 | 100.0 |
Gamma Rays | 5 | 2.0 |
Polytetrafluoroethylene | 2 | 6.0 |
*Power Plants | 3 | 20.0 |
*Radiation Dosage | 3 | 50.0 |
Thermoluminescent Dosimetry/*instrumentation | 9 | 100.0 |
X-Rays | 6 | 5.0 |
Biopsy | 6 | 0.0 |
Embryo Implantation | 5 | 14.0 |
Estradiol/blood | 2 | 0.0 |
Growth Inhibitors/*analysis | 7 | 53.0 |
Infertility, Female/therapy | 2 | 28.0 |
*Interleukin-6 | 318 | 88.0 |
Lymphokines/*analysis | 10 | 6.0 |
Pregnancy | 70 | 1.0 |
Progesterone/blood | 2 | 0.0 |
Gene Expression Regulation | 16 | 0.0 |
Hormones/*physiology | 2 | 4.0 |
Mice | 196 | 0.0 |
Mice, Knockout | 12 | 0.0 |
Models, Biological | 9 | 0.0 |
Uterus/*physiology | 2 | 16.0 |
Cell Differentiation/drug effects | 25 | 2.0 |
Cell Division | 38 | 0.0 |
DNA-Binding Proteins/genetics/physiology | 3 | 3.0 |
Embryo/*cytology | 4 | 12.0 |
Mice, Inbred C3H | 3 | 0.0 |
Mice, Inbred Strains | 5 | 0.0 |
Receptors, Cytokine/physiology | 3 | 11.0 |
Stem Cells/*cytology/drug effects | 5 | 35.0 |
Cytokines/physiology | 8 | 4.0 |
Enzyme Activation | 12 | 0.0 |
Gelatinase A/*metabolism | 2 | 6.0 |
Menstrual Cycle/physiology | 3 | 7.0 |
DNA, Complementary | 7 | 0.0 |
Endometrium/*physiology | 3 | 20.0 |
Growth Inhibitors/*genetics | 28 | 60.0 |
Lymphokines/*genetics | 24 | 11.0 |
Mice, Inbred ICR | 3 | 1.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
RNA, Messenger/*metabolism | 6 | 0.0 |
Receptor, Ciliary Neurotrophic Factor/genetics | 4 | 66.0 |
Receptors, Interleukin-6/genetics | 3 | 50.0 |
Chorionic Gonadotropin/blood | 2 | 2.0 |
Decidua/*metabolism | 4 | 10.0 |
*Gene Expression | 8 | 0.0 |
RNA, Messenger | 2 | 0.0 |
Antigens, CD/metabolism | 13 | 1.0 |
Carrier Proteins/metabolism/pharmacology | 2 | 18.0 |
Cell Division/drug effects | 40 | 1.0 |
Comparative Study | 109 | 0.0 |
Growth Inhibitors/*pharmacology/physiology | 2 | 50.0 |
Interleukin-6/pharmacology | 25 | 9.0 |
*Intracellular Signaling Peptides and Proteins | 3 | 0.0 |
Lymphokines/*pharmacology/physiology | 2 | 28.0 |
Membrane Glycoproteins/metabolism | 15 | 2.0 |
*Repressor Proteins | 8 | 0.0 |
Signal Transduction/drug effects | 5 | 0.0 |
Stem Cells/cytology | 2 | 2.0 |
Antibodies, Monoclonal/metabolism | 5 | 1.0 |
CHO Cells | 8 | 0.0 |
COS Cells | 11 | 0.0 |
Cell Line | 84 | 0.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Cytokines/metabolism | 11 | 2.0 |
DNA-Binding Proteins/metabolism | 18 | 0.0 |
Dimerization | 8 | 0.0 |
Dose-Response Relationship, Drug | 31 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 26 | 0.0 |
Fibronectins/metabolism | 2 | 1.0 |
Flow Cytometry | 16 | 0.0 |
Gene Deletion | 3 | 0.0 |
Hamsters | 15 | 0.0 |
Ligands | 10 | 0.0 |
Mutation | 7 | 0.0 |
Phosphorylation | 29 | 0.0 |
Protein Binding | 18 | 0.0 |
Protein Conformation | 11 | 0.0 |
Protein Structure, Tertiary | 11 | 0.0 |
Receptors, Cytokine/*chemistry/metabolism | 2 | 40.0 |
Trans-Activators/metabolism | 18 | 1.0 |
Transfection | 37 | 0.0 |
Homozygote | 2 | 0.0 |
Hypothalamus/physiology | 2 | 6.0 |
Pituitary Gland/*physiology | 3 | 12.0 |
*Receptors, Cell Surface | 2 | 0.0 |
Binding Sites | 20 | 0.0 |
Chimeric Proteins/chemistry/genetics/metabolism | 2 | 4.0 |
Growth Inhibitors/*metabolism/pharmacology | 6 | 75.0 |
Immunoglobulins/*chemistry | 2 | 13.0 |
Lymphokines/*metabolism/pharmacology | 6 | 23.0 |
Peptides/metabolism | 7 | 3.0 |
Phosphotyrosine/metabolism | 3 | 0.0 |
Blotting, Western | 16 | 0.0 |
Cell Cycle | 2 | 0.0 |
Cytokines/biosynthesis | 7 | 1.0 |
Growth Inhibitors/*metabolism | 35 | 61.0 |
Lymphokines/*metabolism | 37 | 9.0 |
Peptides/*metabolism | 10 | 5.0 |
Receptors, Cytokine/metabolism | 24 | 25.0 |
Growth Inhibitors/*pharmacology | 66 | 36.0 |
Lymphokines/*pharmacology | 66 | 25.0 |
Embryonic and Fetal Development | 5 | 1.0 |
RNA, Messenger/analysis | 29 | 0.0 |
Embryo Implantation/*immunology | 3 | 60.0 |
Fertilization in Vitro | 8 | 6.0 |
Growth Inhibitors/biosynthesis | 3 | 37.0 |
Interleukin-11/biosynthesis | 2 | 40.0 |
Lymphokines/biosynthesis | 8 | 7.0 |
*Pregnancy Outcome | 2 | 3.0 |
Prospective Studies | 10 | 0.0 |
Coculture Techniques | 10 | 1.0 |
Culture Techniques | 10 | 2.0 |
Treatment Failure | 3 | 1.0 |
Treatment Outcome | 4 | 0.0 |
Culture Media, Serum-Free | 4 | 1.0 |
Immunohistochemistry | 34 | 0.0 |
Pregnancy Trimesters | 2 | 14.0 |
Transforming Growth Factor beta/pharmacology | 7 | 2.0 |
*Embryo Implantation | 5 | 20.0 |
Infertility, Female/*metabolism | 2 | 25.0 |
Ovulation Induction | 3 | 7.0 |
Pregnancy Outcome | 2 | 0.0 |
Tumor Necrosis Factor-alpha/analysis | 4 | 0.0 |
Uterus/*metabolism | 4 | 9.0 |
Antigens, CD34/analysis | 2 | 0.0 |
Culture Media, Conditioned | 9 | 2.0 |
Interleukin-11/pharmacology | 7 | 29.0 |
Interleukin-3/pharmacology | 9 | 3.0 |
Mitosis/*drug effects | 2 | 4.0 |
Ploidies | 3 | 1.0 |
Stem Cell Factor/pharmacology | 4 | 2.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
Chorionic Gonadotropin/pharmacology | 3 | 2.0 |
Cytokines/*pharmacology | 23 | 5.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Transcription Factors/metabolism | 4 | 0.0 |
Cell Differentiation/physiology | 10 | 2.0 |
Gene Expression Regulation, Developmental | 4 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Signal Transduction/physiology | 10 | 1.0 |
Embryo Implantation/physiology | 5 | 45.0 |
Embryonic and Fetal Development/physiology | 4 | 4.0 |
Growth Inhibitors/biosynthesis/*physiology | 2 | 50.0 |
Lymphokines/biosynthesis/*physiology | 2 | 13.0 |
Receptors, Cytokine/*physiology | 5 | 19.0 |
Cell Count | 4 | 0.0 |
Cell Survival/drug effects | 11 | 1.0 |
Injections, Intraperitoneal | 2 | 1.0 |
Mice, Transgenic | 10 | 0.0 |
Pilot Projects | 2 | 0.0 |
Superoxide Dismutase/*genetics | 2 | 1.0 |
Growth Inhibitors/*biosynthesis | 22 | 88.0 |
Lymphokines/*biosynthesis | 56 | 21.0 |
Melanoma/metabolism | 2 | 7.0 |
*Ultraviolet Rays | 3 | 1.0 |
In Vitro | 44 | 0.0 |
Nerve Crush | 2 | 20.0 |
Up-Regulation | 9 | 0.0 |
Antigens, CD/*metabolism | 14 | 2.0 |
Cell Differentiation | 37 | 1.0 |
Membrane Glycoproteins/*metabolism | 12 | 2.0 |
Cattle | 18 | 0.0 |
Cytokines/pharmacology | 22 | 5.0 |
Endopeptidases/metabolism | 2 | 1.0 |
Injections, Intra-Articular | 3 | 12.0 |
Interleukin-17/*pharmacology | 2 | 33.0 |
Mice, Inbred C57BL | 14 | 0.0 |
Swine | 12 | 0.0 |
Adolescent | 28 | 0.0 |
*Brain Injuries/diagnosis/pathology/rehabilitation/therapy | 2 | 22.0 |
Family | 2 | 0.0 |
Interleukin-1/*pharmacology | 10 | 2.0 |
Interleukin-6/biosynthesis/*genetics | 4 | 28.0 |
Polymerase Chain Reaction | 32 | 0.0 |
RNA, Messenger/genetics | 12 | 0.0 |
Reference Values | 13 | 0.0 |
Cell Division/physiology | 7 | 0.0 |
Structure-Activity Relationship | 14 | 0.0 |
Cytokines/*biosynthesis | 11 | 2.0 |
Antigens, CD/genetics | 3 | 2.0 |
Fibroblasts/metabolism | 6 | 0.0 |
Interleukin-6/*genetics | 6 | 8.0 |
Membrane Glycoproteins/genetics | 3 | 1.0 |
Tumor Cells, Cultured/metabolism | 3 | 1.0 |
Alleles | 3 | 0.0 |
Exons | 6 | 0.0 |
Genotype | 2 | 0.0 |
*Nuclear Energy | 2 | 66.0 |
Radiation Monitoring/methods/standards | 2 | 100.0 |
Sensitivity and Specificity | 18 | 0.0 |
Thermoluminescent Dosimetry/*methods | 7 | 100.0 |
Estradiol/metabolism | 2 | 2.0 |
*Fertilization in Vitro | 3 | 2.0 |
Follicular Fluid/*metabolism | 3 | 11.0 |
Infertility, Female/metabolism | 3 | 42.0 |
Osmolar Concentration | 4 | 0.0 |
Progesterone/metabolism | 2 | 2.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Embryo/*physiology | 2 | 10.0 |
Growth Inhibitors/*physiology | 11 | 32.0 |
Lymphokines/*physiology | 14 | 11.0 |
Signal Transduction/*physiology | 8 | 0.0 |
*Transcription Factors | 7 | 0.0 |
Cell Division/drug effects/physiology | 3 | 1.0 |
Cytoprotection/drug effects | 2 | 20.0 |
Phenotype | 9 | 0.0 |
Cobalt Radioisotopes/therapeutic use | 3 | 42.0 |
Electrons | 3 | 9.0 |
Photons | 7 | 53.0 |
*Quality Assurance, Health Care | 2 | 9.0 |
Radiotherapy/*instrumentation | 2 | 50.0 |
Thermoluminescent Dosimetry/instrumentation | 2 | 100.0 |
Computer Systems | 3 | 5.0 |
Fluorides | 9 | 75.0 |
Linear Energy Transfer | 4 | 36.0 |
Lithium Compounds | 8 | 100.0 |
Radiation Dosage | 6 | 6.0 |
*Thermoluminescent Dosimetry | 11 | 91.0 |
Blotting, Northern | 25 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Growth Inhibitors/metabolism | 14 | 43.0 |
Immunoblotting | 3 | 0.0 |
Interleukin-6/*metabolism | 7 | 6.0 |
Lymphokines/metabolism | 18 | 8.0 |
MAP Kinase Signaling System | 4 | 1.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 2 | 0.0 |
*Proto-Oncogene Proteins | 10 | 0.0 |
Receptors, Interleukin-6/*metabolism | 3 | 20.0 |
Signal Transduction | 43 | 0.0 |
Tyrphostins/pharmacology | 2 | 1.0 |
DNA Primers/chemistry | 3 | 0.0 |
Peptides/genetics/metabolism | 2 | 4.0 |
Biological Markers/analysis | 2 | 0.0 |
Cell Differentiation/drug effects/*physiology | 3 | 4.0 |
Embryo | 3 | 0.0 |
Epidermal Growth Factor/pharmacology | 3 | 0.0 |
Fetus | 6 | 1.0 |
Fibroblast Growth Factor 2/pharmacology | 4 | 1.0 |
Gestational Age | 3 | 0.0 |
Interleukin-1/pharmacology | 24 | 3.0 |
Kinetics | 34 | 0.0 |
Nerve Tissue Proteins/pharmacology | 3 | 7.0 |
Neurons/*cytology | 5 | 8.0 |
Interleukin-6/*pharmacology | 16 | 7.0 |
Cell Adhesion/drug effects | 3 | 0.0 |
Cell Aggregation/drug effects | 2 | 4.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 7 | 0.0 |
Trans-Activators/genetics/metabolism | 3 | 1.0 |
Cloning, Molecular | 25 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Mutation/genetics | 4 | 0.0 |
Swine/*genetics | 2 | 1.0 |
Acute Disease | 4 | 0.0 |
Solubility | 15 | 1.0 |
Disease Models, Animal | 6 | 0.0 |
*Inflammation | 2 | 5.0 |
Chronic Disease | 4 | 0.0 |
Gene Expression/physiology | 2 | 0.0 |
RNA, Messenger/metabolism | 32 | 0.0 |
Animals, Newborn | 4 | 0.0 |
Cercopithecus aethiops | 8 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 4 | 0.0 |
Recombinant Proteins/metabolism | 9 | 0.0 |
Sequence Deletion | 3 | 0.0 |
*Gene Expression Regulation | 6 | 0.0 |
Growth Inhibitors/biosynthesis/*genetics | 5 | 83.0 |
Lymphokines/biosynthesis/*genetics | 5 | 15.0 |
Cell Aggregation | 3 | 2.0 |
Cell Culture Techniques | 6 | 1.0 |
Ciliary Neurotrophic Factor/*pharmacology | 2 | 40.0 |
Gene Expression Regulation, Neoplastic/drug effects | 5 | 1.0 |
Interleukin-11/*pharmacology | 4 | 25.0 |
Pituitary Gland, Anterior/cytology/*drug effects | 2 | 100.0 |
Rats, Sprague-Dawley | 9 | 0.0 |
Receptors, Cytokine/genetics | 5 | 15.0 |
Chorionic Gonadotropin/*pharmacology | 3 | 5.0 |
Cyclic AMP/metabolism | 3 | 0.0 |
Dinoprostone/pharmacology | 4 | 4.0 |
Forskolin/pharmacology | 2 | 0.0 |
Gene Expression/drug effects | 7 | 0.0 |
Growth Inhibitors/genetics/*pharmacology | 2 | 100.0 |
Lymphokines/genetics/*pharmacology | 2 | 28.0 |
Case-Control Studies | 10 | 0.0 |
Interleukin-8/*metabolism | 2 | 3.0 |
Astrocytes/cytology | 2 | 13.0 |
Cell Lineage | 3 | 0.0 |
Fetus/cytology | 2 | 3.0 |
Glial Fibrillary Acidic Protein/analysis | 2 | 1.0 |
Stem Cells/*cytology | 5 | 5.0 |
Analysis of Variance | 9 | 0.0 |
In Situ Hybridization | 7 | 0.0 |
Recombinant Proteins/pharmacology | 46 | 2.0 |
Growth Inhibitors/*metabolism/physiology | 2 | 100.0 |
Lymphokines/*metabolism/physiology | 2 | 25.0 |
Protein-Tyrosine Kinase/metabolism | 8 | 0.0 |
Equipment Design | 3 | 2.0 |
*Synchrotrons | 2 | 50.0 |
Thermoluminescent Dosimetry/instrumentation/*methods | 2 | 100.0 |
*Hematopoiesis | 2 | 1.0 |
Hematopoietic Stem Cells/cytology | 2 | 2.0 |
Mice, Inbred BALB C | 8 | 0.0 |
Antigens, CD/chemistry/*metabolism | 2 | 5.0 |
Chimeric Proteins/metabolism | 4 | 2.0 |
Cytoplasm/chemistry | 2 | 1.0 |
Mitogen-Activated Protein Kinase 1/*metabolism | 2 | 1.0 |
Mitogen-Activated Protein Kinase 3 | 4 | 0.0 |
Receptors, Cytokine/chemistry/genetics/*metabolism | 2 | 33.0 |
Carrier Proteins/*physiology | 2 | 0.0 |
Cytokines/immunology | 4 | 2.0 |
Growth Substances/immunology | 2 | 20.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Cell Cycle/*physiology | 2 | 0.0 |
Cytokines/*physiology | 12 | 6.0 |
Tetradecanoylphorbol Acetate/pharmacology | 5 | 0.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Interferon Type II/pharmacology | 5 | 0.0 |
Cytokines/*immunology | 6 | 6.0 |
Interleukin-6/*immunology | 2 | 16.0 |
Signal Transduction/*immunology | 5 | 1.0 |
Growth Inhibitors/immunology/*metabolism | 2 | 100.0 |
Lipopolysaccharides | 3 | 2.0 |
Lymphocyte Activation | 23 | 0.0 |
Lymphokines/immunology/*metabolism | 2 | 25.0 |
Mitogens/pharmacology | 2 | 0.0 |
Bone Marrow Cells | 12 | 2.0 |
Gene Expression Regulation/drug effects | 8 | 0.0 |
Hematopoiesis/*drug effects | 2 | 2.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
DNA, Viral/analysis | 2 | 0.0 |
Gene Expression | 30 | 0.0 |
Growth Inhibitors/pharmacology/*physiology | 5 | 62.0 |
Lymphokines/pharmacology/*physiology | 5 | 33.0 |
Monocytes/drug effects | 2 | 3.0 |
Viral Load | 2 | 0.0 |
Collagen/biosynthesis | 2 | 4.0 |
Interleukin-4/pharmacology | 3 | 0.0 |
Interleukin-6/biosynthesis | 3 | 1.0 |
Joints/*metabolism | 2 | 100.0 |
Th2 Cells/*metabolism | 2 | 8.0 |
Cytokines/*genetics | 4 | 2.0 |
Growth Inhibitors/genetics | 4 | 30.0 |
Interleukin-1/genetics | 3 | 4.0 |
Lymphokines/genetics | 4 | 4.0 |
Peptides/genetics | 2 | 2.0 |
Gene Expression Profiling | 4 | 0.0 |
Stem Cells/cytology/*physiology | 3 | 11.0 |
Endometrium/cytology/*metabolism | 3 | 10.0 |
Epithelium/drug effects/metabolism | 3 | 5.0 |
Electrophoresis, Polyacrylamide Gel | 7 | 0.0 |
Interleukin-1/metabolism | 4 | 1.0 |
Interleukin-6/metabolism | 11 | 4.0 |
Osteoblasts/*metabolism | 3 | 5.0 |
Blastocyst/drug effects | 2 | 40.0 |
Amino Acid Motifs | 4 | 0.0 |
DNA-Binding Proteins/physiology | 2 | 0.0 |
Genes, Structural | 4 | 0.0 |
Growth Inhibitors/physiology | 3 | 13.0 |
Lymphokines/physiology | 3 | 3.0 |
Sequence Homology, Nucleic Acid | 8 | 0.0 |
Species Specificity | 13 | 0.0 |
Trans-Activators/physiology | 2 | 1.0 |
Menstrual Cycle/*physiology | 3 | 5.0 |
Stromal Cells/*metabolism | 3 | 8.0 |
Interleukin-10/physiology | 2 | 8.0 |
Pregnancy/*immunology | 2 | 3.0 |
Th2 Cells/*physiology | 2 | 16.0 |
*Apoptosis | 2 | 0.0 |
Sheep | 6 | 1.0 |
Child, Preschool | 20 | 0.0 |
Infant | 13 | 0.0 |
Interleukin-5/pharmacology | 2 | 7.0 |
Mitogen-Activated Protein Kinases/metabolism | 5 | 0.0 |
Protein-Tyrosine-Phosphatase/metabolism | 3 | 2.0 |
Proteins/metabolism | 5 | 0.0 |
Growth Inhibitors/blood | 5 | 50.0 |
Interleukin-6/blood | 6 | 1.0 |
Lymphokines/blood | 5 | 8.0 |
Predictive Value of Tests | 5 | 0.0 |
Iridium Radioisotopes/*therapeutic use | 4 | 80.0 |
Radiotherapy Planning, Computer-Assisted | 2 | 16.0 |
Thermoluminescent Dosimetry | 6 | 85.0 |
X-Ray Film | 3 | 75.0 |
Blastocyst | 3 | 25.0 |
Cryopreservation | 2 | 1.0 |
*Embryonic and Fetal Development | 4 | 3.0 |
Antigens, CD/immunology | 2 | 0.0 |
Chorionic Gonadotropin/*secretion | 2 | 14.0 |
*Growth Inhibitors | 30 | 53.0 |
*Lymphokines | 33 | 75.0 |
Membrane Glycoproteins/immunology | 2 | 1.0 |
Macaca mulatta | 4 | 0.0 |
Menstrual Cycle/*metabolism | 4 | 13.0 |
Receptors, Cytokine/*analysis | 4 | 25.0 |
Tissue Distribution | 3 | 0.0 |
Blastocyst/physiology | 2 | 10.0 |
Embryo/physiology | 2 | 5.0 |
Growth Inhibitors/metabolism/*pharmacology | 3 | 33.0 |
Lymphokines/metabolism/*pharmacology | 2 | 14.0 |
RNA, Messenger/analysis/biosynthesis | 8 | 3.0 |
Corticotropin/secretion | 3 | 4.0 |
Phosphorylation/drug effects | 6 | 0.0 |
Pro-Opiomelanocortin/genetics | 4 | 22.0 |
Transcription Factors/genetics | 3 | 0.0 |
Tyrosine/metabolism | 5 | 0.0 |
Retrospective Studies | 2 | 0.0 |
3T3 Cells | 8 | 0.0 |
Down-Regulation | 7 | 0.0 |
Mitogen-Activated Protein Kinases/*physiology | 2 | 2.0 |
Receptors, Cytokine/*metabolism | 19 | 22.0 |
Growth Inhibitors/chemistry/genetics/*physiology | 2 | 66.0 |
Hematopoiesis | 9 | 3.0 |
Lymphokines/chemistry/genetics/*physiology | 2 | 50.0 |
Molecular Structure | 6 | 0.0 |
Receptors, Cytokine/genetics/physiology | 2 | 66.0 |
DNA Primers/genetics | 8 | 0.0 |
Growth Inhibitors/genetics/*metabolism | 4 | 50.0 |
Lymphokines/genetics/*metabolism | 4 | 4.0 |
Receptors, Cytokine/genetics/*metabolism | 5 | 16.0 |
Steroids/*biosynthesis | 2 | 3.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 2 | 0.0 |
*Milk Proteins | 6 | 1.0 |
Precipitin Tests | 5 | 0.0 |
*Signal Transduction | 21 | 1.0 |
Thymidine/metabolism | 7 | 2.0 |
Radiation Protection | 2 | 66.0 |
Temperature | 5 | 0.0 |
Embryo/cytology/*metabolism | 2 | 33.0 |
Endometrium/cytology/drug effects/*metabolism | 2 | 15.0 |
Placenta/*metabolism | 3 | 1.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
Growth Inhibitors/*chemistry | 6 | 54.0 |
Lymphokines/*chemistry | 6 | 54.0 |
Nitrogen Isotopes | 2 | 5.0 |
Colony-Forming Units Assay | 9 | 1.0 |
Genetic Vectors | 8 | 0.0 |
Mesoderm/cytology/*physiology | 2 | 25.0 |
Retroviridae | 2 | 2.0 |
Immunohistochemistry/methods | 6 | 0.0 |
Microscopy, Electron, Scanning | 4 | 1.0 |
Receptors, Cytokine/genetics/*physiology | 2 | 22.0 |
Transcription Factors/genetics/physiology | 2 | 3.0 |
Antigens, CD34/metabolism | 4 | 1.0 |
Cell Culture Techniques/*methods | 5 | 5.0 |
*Hematopoietic Stem Cell Transplantation | 2 | 0.0 |
Hematopoietic Stem Cells/*cytology | 4 | 1.0 |
Mice, SCID | 2 | 0.0 |
Glomerular Mesangium/cytology/metabolism | 2 | 25.0 |
*Radiotherapy Dosage | 10 | 71.0 |
Cell Separation | 9 | 0.0 |
Indicators and Reagents | 3 | 1.0 |
Macrophages/metabolism | 2 | 0.0 |
Antibodies/pharmacology | 6 | 1.0 |
Keratinocytes/*metabolism | 2 | 2.0 |
Cytokines/*metabolism | 10 | 3.0 |
Epitopes/metabolism | 2 | 3.0 |
Models, Molecular | 14 | 0.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Peptide Library | 3 | 2.0 |
Protein Structure, Secondary | 4 | 0.0 |
Sequence Homology, Amino Acid | 25 | 0.0 |
Membrane Glycoproteins/*pharmacology | 3 | 3.0 |
Peptides/*pharmacology | 14 | 6.0 |
Proteoglycans/*metabolism | 2 | 3.0 |
Corticotropin-Releasing Hormone/*genetics | 2 | 22.0 |
Dexamethasone/pharmacology | 11 | 2.0 |
Placenta/physiology | 3 | 8.0 |
Plasmids | 2 | 0.0 |
Cell Count/drug effects | 2 | 2.0 |
Cell Differentiation/drug effects/physiology | 2 | 2.0 |
Embryo/metabolism | 2 | 1.0 |
Platelet-Derived Growth Factor/pharmacology | 3 | 1.0 |
Gene Expression Regulation/immunology | 2 | 1.0 |
Transforming Growth Factor beta/genetics | 2 | 2.0 |
Bone and Bones/metabolism | 2 | 3.0 |
Inflammation/*metabolism | 3 | 5.0 |
Interleukin-6/*physiology | 9 | 11.0 |
Culture Media | 9 | 1.0 |
Embryo Transfer | 4 | 5.0 |
Growth Inhibitors/*secretion | 3 | 60.0 |
Lymphokines/*secretion | 6 | 14.0 |
Arthritis, Rheumatoid/*metabolism/pathology | 2 | 5.0 |
Interleukin-11/*biosynthesis | 2 | 100.0 |
Osteoarthritis/*metabolism/pathology | 3 | 25.0 |
Antigens, CD/*physiology | 5 | 1.0 |
Lipopolysaccharides/pharmacology | 7 | 0.0 |
Membrane Glycoproteins/*physiology | 6 | 2.0 |
Pituitary Gland/metabolism | 2 | 3.0 |
Fibroblasts/*metabolism | 2 | 1.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Interleukin-6/*biosynthesis | 7 | 6.0 |
Biological Markers | 5 | 0.0 |
Chimera | 3 | 1.0 |
DNA/genetics/metabolism | 3 | 0.0 |
Stem Cells/*cytology/metabolism | 3 | 11.0 |
Macrophages/*metabolism | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Carcinoma, Hepatocellular | 3 | 0.0 |
Macromolecular Substances | 10 | 0.0 |
Receptors, Cytokine/genetics/metabolism/*physiology | 2 | 66.0 |
Receptors, Interleukin/metabolism | 3 | 5.0 |
Cell Survival/physiology | 2 | 1.0 |
Liver/metabolism | 4 | 0.0 |
Peptides/metabolism/*pharmacology | 5 | 20.0 |
Protein-Tyrosine Kinase/*metabolism | 5 | 0.0 |
NF-kappa B/*metabolism | 2 | 0.0 |
Nitric-Oxide Synthase/metabolism | 2 | 1.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Cell Movement/drug effects | 12 | 3.0 |
Enzyme Induction | 2 | 0.0 |
Neovascularization, Physiologic/*drug effects | 2 | 2.0 |
Blastocyst/*metabolism | 2 | 8.0 |
Blotting, Southern | 7 | 0.0 |
Biophysics | 3 | 6.0 |
*Brachytherapy | 2 | 22.0 |
Evaluation Studies | 4 | 0.0 |
Monte Carlo Method | 2 | 2.0 |
Radiotherapy Dosage | 11 | 7.0 |
Water | 3 | 5.0 |
Recombinant Fusion Proteins/genetics | 3 | 1.0 |
Oligonucleotide Probes | 3 | 0.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 2 | 2.0 |
*Gene Expression Regulation/drug effects | 3 | 1.0 |
Genes, Reporter | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Recombinant Fusion Proteins/biosynthesis | 3 | 0.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 11 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 5 | 1.0 |
*Hematopoietic Stem Cell Mobilization | 2 | 3.0 |
*Cell Adhesion | 2 | 1.0 |
Cell Division/*drug effects | 6 | 2.0 |
Interleukin-3/*pharmacology | 2 | 1.0 |
Megakaryocytes/*cytology | 2 | 3.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 2 | 0.0 |
Glycosylation | 3 | 0.0 |
Receptor, IGF Type 2/*metabolism | 2 | 16.0 |
Gene Therapy | 2 | 0.0 |
Retroviridae/*genetics | 2 | 1.0 |
*Transduction, Genetic | 2 | 2.0 |
Interleukin-8/biosynthesis | 2 | 1.0 |
Receptors, Cell Surface/physiology | 2 | 1.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Growth Inhibitors/*biosynthesis/blood | 2 | 100.0 |
Lymphokines/*biosynthesis/blood | 2 | 14.0 |
Macaca fascicularis | 2 | 0.0 |
Calibration | 4 | 2.0 |
Particle Accelerators | 3 | 25.0 |
Phantoms, Imaging | 4 | 18.0 |
Acid Phosphatase/analysis | 2 | 2.0 |
Antigens, CD/analysis | 2 | 0.0 |
Kidney | 3 | 0.0 |
Antigens, CD/genetics/metabolism | 3 | 5.0 |
Membrane Glycoproteins/genetics/metabolism | 3 | 3.0 |
Mutagenesis | 2 | 0.0 |
Stem Cells/cytology/*metabolism | 2 | 5.0 |
Antigens, CD/biosynthesis | 3 | 0.0 |
Apoptosis/drug effects | 3 | 0.0 |
Calcimycin/pharmacology | 3 | 1.0 |
Growth Inhibitors/*biosynthesis/genetics/pharmacology | 3 | 100.0 |
Lymphokines/*biosynthesis/genetics/pharmacology | 3 | 37.0 |
Stimulation, Chemical | 9 | 1.0 |
Prostatic Neoplasms/*pathology | 2 | 1.0 |
Cell Differentiation/drug effects/genetics | 2 | 3.0 |
Transcription, Genetic/drug effects | 5 | 0.0 |
Tretinoin/pharmacology | 3 | 0.0 |
*Transfection | 2 | 0.0 |
Interleukin-11/physiology | 2 | 50.0 |
Infertility, Female/*genetics | 2 | 16.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Growth Inhibitors/*analysis/immunology | 2 | 100.0 |
Lymphokines/*analysis/immunology | 2 | 25.0 |
Binding Sites/genetics | 4 | 0.0 |
Protein Folding | 2 | 0.0 |
Ciliary Neurotrophic Factor | 27 | 22.0 |
Growth Inhibitors/*blood | 8 | 42.0 |
Growth Substances/blood | 2 | 15.0 |
Interleukin-11/blood | 2 | 15.0 |
Interleukin-6/*blood | 6 | 2.0 |
Lymphokines/*blood | 12 | 4.0 |
Multiple Myeloma/*blood | 2 | 8.0 |
Nerve Tissue Proteins/blood | 4 | 44.0 |
Peptides/blood | 3 | 8.0 |
Receptors, Interleukin-6/*blood | 4 | 30.0 |
Tretinoin/*pharmacology | 3 | 0.0 |
Tumor Cells, Cultured/drug effects | 3 | 0.0 |
Biological Markers/blood | 4 | 0.0 |
Lymphocytes/drug effects/*immunology | 3 | 7.0 |
Phytohemagglutinins/pharmacology | 16 | 3.0 |
Cell Communication/*physiology | 3 | 4.0 |
Growth Substances/genetics/metabolism | 2 | 15.0 |
Hematopoietic Stem Cells/*cytology/drug effects | 2 | 2.0 |
Interleukin-6/chemistry/*metabolism | 3 | 75.0 |
Nerve Tissue Proteins/chemistry/*metabolism | 2 | 6.0 |
*Chemotaxis, Leukocyte | 3 | 4.0 |
Lung/*immunology | 2 | 4.0 |
Molecular Weight | 12 | 0.0 |
Adrenal Glands/*physiology | 2 | 14.0 |
Corticotropin/*secretion | 2 | 4.0 |
Hypothalamus/*physiology | 2 | 7.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Endometrial Neoplasms/*genetics/pathology | 2 | 6.0 |
Prognosis | 4 | 0.0 |
Interleukin-1/*physiology | 4 | 4.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Receptors, Cytokine/chemistry/*metabolism | 2 | 33.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
Bone Marrow/drug effects/*metabolism | 2 | 33.0 |
Growth Inhibitors/*biosynthesis/genetics | 7 | 87.0 |
Interleukin-10/pharmacology | 2 | 2.0 |
Interleukin-4/*pharmacology | 5 | 2.0 |
Interleukin-6/*biosynthesis/genetics | 3 | 8.0 |
Lymphokines/*biosynthesis/genetics | 8 | 6.0 |
Stromal Cells/metabolism | 5 | 5.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
Cell Nucleus/metabolism | 4 | 0.0 |
*Mitogen-Activated Protein Kinases | 3 | 0.0 |
*Cell Differentiation | 3 | 1.0 |
Leukemia, Myeloid/*pathology | 5 | 9.0 |
Point Mutation | 3 | 0.0 |
Recombinant Fusion Proteins | 3 | 0.0 |
Disease Progression | 5 | 0.0 |
Growth Inhibitors/analysis | 2 | 100.0 |
Interleukin-1/analysis | 4 | 4.0 |
Interleukin-6/genetics/*physiology | 2 | 33.0 |
Lymphokines/analysis | 3 | 3.0 |
*Multigene Family | 2 | 0.0 |
Peptides/analysis | 2 | 2.0 |
Antigens, CD/physiology | 3 | 1.0 |
Membrane Glycoproteins/physiology | 3 | 1.0 |
Nerve Tissue Proteins/*pharmacology | 6 | 6.0 |
Recombinant Proteins | 11 | 1.0 |
Cell Communication | 6 | 2.0 |
Chromosome Mapping | 12 | 0.0 |
DNA, Complementary/genetics | 6 | 0.0 |
Receptors, Cytokine/*chemistry | 2 | 33.0 |
Sequence Alignment | 11 | 0.0 |
DNA/biosynthesis | 5 | 0.0 |
Ganglia, Spinal/cytology | 2 | 8.0 |
Nerve Growth Factors/pharmacology | 4 | 4.0 |
Nerve Regeneration/*physiology | 2 | 7.0 |
Spectroscopy, Fourier Transform Infrared | 2 | 4.0 |
Peptide Fragments/*pharmacology | 2 | 1.0 |
Alkaline Phosphatase/metabolism | 2 | 1.0 |
Growth Substances/pharmacology | 4 | 2.0 |
Histocytochemistry | 3 | 0.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 2 | 1.0 |
Hematopoietic Stem Cells/*cytology/drug effects/physiology | 3 | 33.0 |
Mice, Neurologic Mutants | 2 | 1.0 |
Interleukin-6/*metabolism/pharmacology | 3 | 16.0 |
Mesoderm/*cytology | 4 | 14.0 |
Receptors, Interleukin-6/metabolism | 4 | 14.0 |
Bone Marrow Cells/*metabolism | 2 | 4.0 |
Leukotriene B4/pharmacology | 2 | 11.0 |
Apoptosis/*physiology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/physiology | 3 | 1.0 |
Chick Embryo | 3 | 0.0 |
RNA, Antisense | 2 | 3.0 |
Recombinant Proteins/biosynthesis | 3 | 0.0 |
Vasoactive Intestinal Peptide/*genetics | 4 | 21.0 |
Epidermal Growth Factor/physiology | 3 | 3.0 |
Pregnancy Trimester, First | 3 | 1.0 |
Transforming Growth Factor beta/physiology | 2 | 2.0 |
Inflammation | 2 | 0.0 |
Interleukin-6/*secretion | 2 | 5.0 |
Embryonic and Fetal Development/*physiology | 3 | 6.0 |
*Infertility, Female | 2 | 100.0 |
Cell Division/genetics | 2 | 0.0 |
Cytokines/genetics/*metabolism | 3 | 8.0 |
Epithelial Cells/metabolism | 3 | 0.0 |
Mink | 2 | 3.0 |
Open Reading Frames | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/metabolism | 2 | 3.0 |
Stem Cell Factor/metabolism | 2 | 8.0 |
Transforming Growth Factor beta/metabolism | 3 | 1.0 |
Crystallography, X-Ray | 9 | 1.0 |
Granulocyte Colony-Stimulating Factor/chemistry | 2 | 66.0 |
Growth Inhibitors/chemistry | 2 | 100.0 |
Lymphokines/chemistry | 2 | 50.0 |
Nuclear Magnetic Resonance, Biomolecular | 2 | 1.0 |
Granulocyte Colony-Stimulating Factor/*chemistry | 3 | 75.0 |
Magnetic Resonance Spectroscopy | 5 | 0.0 |
Granulosa Cells/metabolism | 2 | 5.0 |
Growth Inhibitors/analysis/*biosynthesis | 4 | 100.0 |
Interleukin-2/*biosynthesis | 2 | 1.0 |
Lymphokines/analysis/*biosynthesis | 6 | 23.0 |
Fertilization in Vitro/*methods | 2 | 7.0 |
Interleukin-6/physiology | 3 | 4.0 |
Membrane Glycoproteins/biosynthesis | 3 | 1.0 |
Receptors, Cytokine/*biosynthesis | 4 | 30.0 |
Corticotropin/metabolism | 2 | 5.0 |
Gene Expression Regulation/*drug effects | 4 | 0.0 |
Radioimmunoassay | 5 | 0.0 |
DNA-Binding Proteins/analysis | 2 | 2.0 |
Interleukin-6/*analysis | 4 | 10.0 |
Leptin/*pharmacology | 2 | 6.0 |
Drug Combinations | 2 | 0.0 |
Peptides/metabolism/pharmacology | 2 | 12.0 |
Solutions | 3 | 1.0 |
Antigens, CD34/immunology | 2 | 3.0 |
Bone Marrow/metabolism | 3 | 2.0 |
Clone Cells/*cytology | 2 | 50.0 |
Culture Techniques/*methods | 2 | 9.0 |
Fetal Blood/metabolism | 2 | 3.0 |
Growth Substances/*physiology | 4 | 2.0 |
Chromatography, Gel | 14 | 1.0 |
Breast Neoplasms/*metabolism/pathology | 2 | 1.0 |
Corticosterone/blood | 3 | 8.0 |
Corticotropin/blood | 2 | 1.0 |
Sialoglycoproteins/pharmacology | 2 | 15.0 |
Hematopoietic Stem Cells/pathology | 2 | 5.0 |
Cartilage, Articular/drug effects/*metabolism | 2 | 50.0 |
Computer Simulation | 2 | 0.0 |
Electrostatics | 2 | 1.0 |
Protein Binding/physiology | 2 | 0.0 |
DNA/chemistry/metabolism | 2 | 2.0 |
Neuroblastoma | 3 | 1.0 |
Recombinant Proteins/biosynthesis/pharmacology | 2 | 6.0 |
*Transcription, Genetic/drug effects | 2 | 1.0 |
Biological Assay | 5 | 1.0 |
Reproducibility of Results | 10 | 0.0 |
Tyrosine/*metabolism | 2 | 0.0 |
Interleukin-1/immunology | 3 | 6.0 |
Skin/cytology | 2 | 1.0 |
Synovial Membrane/cytology | 2 | 11.0 |
Integrins/*metabolism | 2 | 1.0 |
RNA/metabolism | 2 | 0.0 |
Acute-Phase Proteins/biosynthesis | 3 | 23.0 |
Brain/metabolism | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 5 | 0.0 |
Embryo Implantation/immunology | 2 | 28.0 |
Antibodies/immunology/pharmacology | 2 | 6.0 |
Bromodeoxyuridine/metabolism | 4 | 5.0 |
Cell Differentiation/*drug effects | 5 | 3.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
Estradiol/*pharmacology | 3 | 1.0 |
Promoter Regions (Genetics) | 10 | 0.0 |
Nerve Tissue Proteins/*genetics | 2 | 0.0 |
Trans-Activators/*physiology | 2 | 0.0 |
Antineoplastic Agents/pharmacology | 3 | 0.0 |
Growth Substances/metabolism | 2 | 1.0 |
Interleukin-6/*chemistry | 2 | 66.0 |
*Protein Structure, Tertiary | 2 | 1.0 |
Organ Specificity | 5 | 0.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 2 | 0.0 |
Goats | 4 | 4.0 |
Leukocyte Count/drug effects | 2 | 1.0 |
Epithelium/physiology | 2 | 2.0 |
Cyclic AMP/pharmacology | 2 | 1.0 |
Immunophenotyping | 2 | 0.0 |
Immune Sera/immunology | 2 | 1.0 |
Ionomycin/pharmacology | 2 | 0.0 |
Phorbol Esters/pharmacology | 3 | 2.0 |
RNA, Messenger/analysis/genetics | 3 | 0.0 |
DNA/*genetics | 2 | 0.0 |
*Mutation | 4 | 0.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 8 | 0.0 |
Cytokines/*blood | 4 | 1.0 |
Multiple Sclerosis/*drug therapy/metabolism | 2 | 50.0 |
Pregnancy Rate | 3 | 2.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Embryonic Development/*physiology | 2 | 14.0 |
Growth Inhibitors/biosynthesis/genetics/physiology | 2 | 66.0 |
Lymphokines/biosynthesis/genetics/physiology | 2 | 66.0 |
Growth Inhibitors/genetics/*physiology | 2 | 33.0 |
Growth Substances/genetics/*physiology | 2 | 11.0 |
Lymphokines/genetics/*physiology | 2 | 6.0 |
Organ Culture Techniques | 5 | 1.0 |
Osteoblasts/*cytology | 2 | 11.0 |
Osteoclasts/cytology | 2 | 33.0 |
DNA/metabolism | 3 | 0.0 |
Growth Inhibitors/*chemistry/genetics/metabolism | 2 | 100.0 |
Lymphokines/*chemistry/genetics/metabolism | 2 | 33.0 |
Jurkat Cells | 2 | 0.0 |
Cytokines/*analysis | 3 | 3.0 |
Interleukin-6/analysis | 3 | 3.0 |
Receptors, Interleukin/*metabolism | 5 | 15.0 |
Receptors, Interleukin-6 | 18 | 21.0 |
Bone Marrow/*pathology | 3 | 2.0 |
Cell Adhesion | 8 | 0.0 |
Bone Marrow/*drug effects | 2 | 7.0 |
C-Reactive Protein/metabolism | 2 | 0.0 |
Escherichia coli | 4 | 0.0 |
Mice, Nude | 6 | 0.0 |
Inflammation Mediators/physiology | 2 | 7.0 |
Arthritis, Rheumatoid/*blood | 2 | 4.0 |
C-Reactive Protein/analysis | 2 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism | 2 | 0.0 |
Growth Inhibitors/analysis/*biosynthesis/genetics | 3 | 100.0 |
Lymphokines/analysis/*biosynthesis/genetics | 3 | 37.0 |
Prolactin/biosynthesis | 2 | 14.0 |
Gene Expression/*drug effects | 2 | 0.0 |
Receptors, Interleukin/*physiology | 2 | 8.0 |
Umbilical Veins | 2 | 0.0 |
Radiometry | 2 | 11.0 |
*Peptide Biosynthesis | 2 | 6.0 |
Binding, Competitive | 8 | 0.0 |
Protein Binding/immunology | 2 | 1.0 |
Adjuvants, Immunologic/*pharmacology | 3 | 1.0 |
Interleukin-1/*metabolism | 2 | 2.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
*Protein Structure, Secondary | 2 | 1.0 |
Software | 2 | 0.0 |
Guinea Pigs | 5 | 0.0 |
Hematologic Neoplasms/*blood | 2 | 28.0 |
Receptors, Cytokine/analysis | 4 | 26.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Chimeric Proteins/chemistry | 2 | 11.0 |
Magnetic Resonance Spectroscopy/methods | 2 | 4.0 |
Models, Structural | 6 | 3.0 |
*Protein Conformation | 2 | 0.0 |
Tumor Markers, Biological/*blood | 2 | 0.0 |
Bone Marrow/*physiology | 2 | 11.0 |
Receptors, Interleukin/physiology | 2 | 13.0 |
Drug Evaluation, Preclinical | 4 | 2.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Peptides/*blood | 2 | 2.0 |
Bone Marrow/drug effects | 3 | 4.0 |
*Bone Marrow Cells | 6 | 2.0 |
Hematopoiesis/drug effects | 3 | 3.0 |
Stem Cells/drug effects | 2 | 9.0 |
Transplantation, Isogeneic | 2 | 7.0 |
Growth Substances/physiology | 2 | 1.0 |
Recombinant Proteins/therapeutic use | 2 | 0.0 |
Tumor Necrosis Factor-alpha/genetics | 2 | 0.0 |
Corticotropin/blood/*secretion | 2 | 8.0 |
Drug Synergism | 10 | 0.0 |
Recombinant Proteins/administration & dosage/pharmacology | 2 | 3.0 |
Cell Cycle/drug effects | 2 | 0.0 |
Corticotropin-Releasing Hormone/pharmacology | 3 | 8.0 |
Growth Inhibitors/*administration & dosage | 2 | 100.0 |
Lymphokines/*administration & dosage | 2 | 20.0 |
Tritium | 6 | 2.0 |
Vero Cells | 2 | 0.0 |
Laryngeal Neoplasms/*radiotherapy | 2 | 66.0 |
Macrophage Colony-Stimulating Factor/pharmacology | 2 | 2.0 |
Cell Membrane/drug effects/metabolism | 2 | 2.0 |
Receptor, Ciliary Neurotrophic Factor | 8 | 9.0 |
Fibrinogen/biosynthesis | 2 | 18.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Motor Neurons/drug effects/pathology | 2 | 66.0 |
Recombination, Genetic | 2 | 0.0 |
Endotoxins/pharmacology | 2 | 2.0 |
Lipopolysaccharides/*pharmacology | 5 | 1.0 |
Restriction Mapping | 5 | 0.0 |
Protein Biosynthesis | 3 | 0.0 |
Signal Transduction/drug effects/physiology | 3 | 1.0 |
Growth Substances/*pharmacology | 5 | 1.0 |
Calcium/pharmacology | 2 | 0.0 |
Up-Regulation/physiology | 2 | 1.0 |
Blastocyst/metabolism | 2 | 10.0 |
Chickens | 2 | 0.0 |
Aorta | 2 | 1.0 |
Interleukin-6/pharmacology/*physiology | 2 | 18.0 |
Estradiol/pharmacology | 4 | 1.0 |
RNA-Directed DNA Polymerase | 4 | 3.0 |
Fertility | 2 | 7.0 |
Receptors, Cytokine/analysis/*biosynthesis | 2 | 50.0 |
*Chromosome Mapping | 2 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Hybrid Cells | 5 | 0.0 |
Cartilage, Articular/cytology/*metabolism | 2 | 25.0 |
Nerve Growth Factors/*metabolism | 2 | 2.0 |
Nerve Tissue Proteins/*metabolism | 4 | 1.0 |
Radioligand Assay | 5 | 1.0 |
Cross-Linking Reagents | 3 | 0.0 |
China | 2 | 0.0 |
Copper | 4 | 20.0 |
Magnesium | 5 | 20.0 |
Phosphorus | 4 | 50.0 |
Reference Standards | 3 | 1.0 |
Cell Division/radiation effects | 2 | 4.0 |
Lymphocyte Culture Test, Mixed | 4 | 0.0 |
T-Lymphocytes/cytology | 2 | 2.0 |
Nerve Tissue Proteins/physiology | 2 | 4.0 |
Interleukin-1/physiology | 4 | 4.0 |
DNA/genetics | 5 | 0.0 |
Leukocyte Count | 4 | 0.0 |
Epithelial Cells | 3 | 0.0 |
Hydrocortisone/*pharmacology | 2 | 5.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Blastocyst/*physiology | 4 | 25.0 |
Acute-Phase Reaction/*chemically induced | 2 | 40.0 |
Liver Neoplasms/*metabolism | 2 | 2.0 |
Culture Media, Conditioned/chemistry | 2 | 4.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/genetics | 3 | 11.0 |
Interleukin-6/genetics | 3 | 4.0 |
Nerve Growth Factors/*pharmacology | 2 | 1.0 |
Neurons/cytology/*drug effects | 2 | 13.0 |
Clone Cells | 2 | 0.0 |
Introns | 3 | 0.0 |
Neoplasm Transplantation | 3 | 0.0 |
Escherichia coli/genetics | 2 | 0.0 |
Embryonic and Fetal Development/drug effects | 2 | 9.0 |
*Evolution | 2 | 1.0 |
Receptors, Cytokine/biosynthesis | 2 | 11.0 |
Tumor Stem Cell Assay | 2 | 1.0 |
Cytokines/*biosynthesis/physiology | 2 | 40.0 |
*Embryonic Development | 2 | 10.0 |
Arthritis, Rheumatoid/*immunology | 4 | 1.0 |
Chemotactic Factors/*biosynthesis | 2 | 13.0 |
Chemotaxis, Leukocyte | 3 | 1.0 |
Interferon-gamma, Recombinant/*pharmacology | 2 | 1.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 4 | 0.0 |
Embryonic Development/*immunology | 2 | 50.0 |
Lymphokines/immunology | 3 | 15.0 |
*Antigens, CD | 11 | 1.0 |
Macrophage Inflammatory Protein-1 | 2 | 10.0 |
Cobalt Radioisotopes | 3 | 14.0 |
Poland | 3 | 2.0 |
Endometrium/metabolism | 4 | 7.0 |
Molecular Probes/genetics | 2 | 2.0 |
Embryo/cytology | 2 | 2.0 |
Leukemia, Myelocytic, Acute/pathology | 2 | 12.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 1 | 4 | 3.0 |
Protein-Serine-Threonine Kinases/*metabolism | 2 | 0.0 |
Decidua/metabolism | 3 | 10.0 |
*Protein Biosynthesis | 3 | 0.0 |
Cachexia/etiology/*metabolism | 2 | 40.0 |
Lipoprotein Lipase/*antagonists & inhibitors | 2 | 14.0 |
Neoplasms/*metabolism | 2 | 2.0 |
Leukocytes/*drug effects | 3 | 25.0 |
Culture Techniques/methods | 2 | 3.0 |
*Chromosomes, Human, Pair 22 | 8 | 3.0 |
Inflammation/immunology | 2 | 1.0 |
Fibroblasts/*physiology | 2 | 3.0 |
Antibodies/immunology | 2 | 0.0 |
Chorionic Villi/metabolism | 2 | 15.0 |
Bone Marrow/*metabolism/pathology | 4 | 22.0 |
Stem Cell Factor | 2 | 2.0 |
Neutralization Tests | 2 | 0.0 |
Protease Inhibitors | 3 | 17.0 |
Hematopoietic Stem Cells/drug effects | 4 | 6.0 |
Models, Theoretical | 3 | 2.0 |
*Radiotherapy, High-Energy | 2 | 28.0 |
*Bone Marrow Transplantation | 2 | 0.0 |
Gene Expression/genetics | 2 | 0.0 |
Iodine Radioisotopes | 2 | 0.0 |
Escherichia coli/*genetics | 2 | 2.0 |
Growth Inhibitors/chemistry/*genetics | 2 | 66.0 |
Lymphokines/chemistry/*genetics | 2 | 50.0 |
Scattering, Radiation | 3 | 2.0 |
Surface Properties | 2 | 1.0 |
Lymphotoxin/*pharmacology | 2 | 5.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Skin/*radiation effects | 3 | 33.0 |
Bone Marrow Transplantation | 3 | 1.0 |
Neurons/metabolism | 3 | 0.0 |
Copper/chemistry | 4 | 20.0 |
Dose-Response Relationship, Radiation | 2 | 0.0 |
Fluorides/chemistry/*radiation effects | 3 | 100.0 |
Lithium Compounds/chemistry/*radiation effects | 4 | 100.0 |
Luminescent Measurements | 4 | 4.0 |
Magnesium/chemistry | 4 | 20.0 |
Radiochemistry | 5 | 45.0 |
Silicon/chemistry | 2 | 66.0 |
Sodium/chemistry | 2 | 40.0 |
Chromosomes, Human, Pair 22 | 4 | 2.0 |
Linkage (Genetics) | 4 | 0.0 |
*Fluorides | 3 | 100.0 |
*Lithium Compounds | 3 | 100.0 |
Mathematics | 2 | 1.0 |
Probability | 2 | 0.0 |
Radiotherapy/methods | 2 | 25.0 |
Endometrium/immunology | 2 | 16.0 |
Gene Expression/immunology | 2 | 2.0 |
Fetal Blood/cytology | 2 | 1.0 |
Ultraviolet Rays | 2 | 0.0 |
Hydrogen-Ion Concentration | 5 | 0.0 |
Crosses, Genetic | 3 | 0.0 |
Somatomedins/metabolism | 2 | 6.0 |
Oncogenes | 3 | 1.0 |
Bone and Bones/*cytology | 2 | 20.0 |
Skin/*immunology | 2 | 1.0 |
Cell Survival | 2 | 0.0 |
Membrane Glycoproteins/*metabolism/physiology | 2 | 13.0 |
Cytokines/pharmacology/*physiology | 2 | 8.0 |
Phosphotyrosine | 2 | 0.0 |
RNA/analysis | 2 | 0.0 |
*Chromosome Aberrations | 2 | 0.0 |
Genetic Markers | 3 | 0.0 |
Methylation | 2 | 0.0 |
Evolution | 2 | 0.0 |
Growth Inhibitors/biosynthesis/*metabolism | 2 | 100.0 |
Nerve Tissue Proteins/metabolism | 2 | 0.0 |
Isoelectric Focusing | 3 | 0.0 |
Blood Coagulation/drug effects | 2 | 1.0 |
T-Lymphocytes/*immunology | 6 | 0.0 |
Cosmids | 2 | 0.0 |
DNA Probes | 4 | 0.0 |
Lymphocyte Activation/drug effects | 10 | 1.0 |
Cartilage/*metabolism | 2 | 10.0 |
Synovial Fluid/cytology | 2 | 8.0 |
*Receptors, Cytokine | 12 | 8.0 |
Immune Sera | 2 | 0.0 |
Administration, Oral | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay/methods | 2 | 0.0 |
Syndrome | 2 | 0.0 |
Indomethacin/pharmacology | 5 | 2.0 |
Cells, Cultured/drug effects | 2 | 2.0 |
Growth Inhibitors/secretion | 2 | 66.0 |
Lymphokines/secretion | 2 | 5.0 |
Macrophages/*immunology | 3 | 1.0 |
T-Lymphocytes/immunology | 9 | 0.0 |
Sarcoma, Ewing's/*genetics | 2 | 4.0 |
Cytochalasin B/pharmacology | 3 | 3.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 2 | 0.0 |
Interleukin-2/pharmacology | 2 | 0.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Epitopes | 3 | 0.0 |
Receptors, Immunologic/genetics/*metabolism | 2 | 5.0 |
Blotting, Western/methods | 4 | 2.0 |
Transforming Growth Factor alpha/pharmacology | 2 | 2.0 |
Arthritis/*etiology | 2 | 66.0 |
Receptors, Immunologic/physiology | 3 | 2.0 |
Irrigation | 2 | 3.0 |
Risk Assessment | 2 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Hematopoietic Stem Cells/*physiology | 2 | 1.0 |
Cell Line, Tumor | 2 | 0.0 |
Lymphokines | 2 | 18.0 |
Chemotaxis, Leukocyte/drug effects | 2 | 2.0 |
Cytotoxicity, Immunologic | 2 | 0.0 |
Receptors, Immunologic | 2 | 5.0 |
Chromosome Banding | 2 | 0.0 |
Receptors, Immunologic/*genetics | 2 | 1.0 |
Gene Rearrangement | 2 | 0.0 |
Recombinant Proteins/analysis | 2 | 4.0 |
Substrate Specificity | 3 | 0.0 |
Haplorhini | 2 | 0.0 |
Neutrophils/drug effects/*physiology | 2 | 3.0 |
Phagocytosis/drug effects | 2 | 2.0 |
Radiotherapy Planning, Computer-Assisted/*methods | 2 | 50.0 |
Granulocyte Colony-Stimulating Factor | 3 | 15.0 |
Immunity | 2 | 3.0 |
Colony-Stimulating Factors/*pharmacology | 2 | 4.0 |
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Brachytherapy/instrumentation/*methods | 3 | 100.0 |
Iridium Radioisotopes/therapeutic use | 2 | 66.0 |
T-Lymphocytes/*metabolism | 3 | 0.0 |
Growth Inhibitors/metabolism/*physiology | 2 | 50.0 |
Immunity, Cellular/*drug effects | 4 | 9.0 |
Leukocyte Migration-Inhibitory Factors/analysis | 6 | 85.0 |
Recurrence | 6 | 0.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 2 | 1.0 |
Concanavalin A/pharmacology | 12 | 5.0 |
Leukocyte Migration-Inhibitory Factors/*biosynthesis | 19 | 95.0 |
Methods | 6 | 2.0 |
B-Lymphocytes/immunology | 3 | 0.0 |
Immunoglobulin M/biosynthesis | 2 | 2.0 |
Interleukin-1/biosynthesis | 3 | 1.0 |
Cell Migration Inhibition | 27 | 26.0 |
Pneumonia/*chemically induced/immunology | 2 | 100.0 |
Receptors, Complement 3b | 2 | 0.0 |
Proteins/genetics | 2 | 0.0 |
Immunity, Cellular | 12 | 1.0 |
Leukocyte Migration-Inhibitory Factors | 3 | 75.0 |
Milk/*adverse effects | 2 | 28.0 |
Colony-Stimulating Factors/metabolism | 2 | 28.0 |
Monocytes/*metabolism | 2 | 0.0 |
*Proteins | 4 | 0.0 |
Neutrophils/*immunology | 8 | 4.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Neutrophils/*physiology | 3 | 2.0 |
Phagocytosis | 2 | 0.0 |
Rosette Formation | 8 | 2.0 |
Superoxides/biosynthesis | 2 | 20.0 |
Antigens, Bacterial/immunology | 4 | 3.0 |
HLA Antigens/genetics | 2 | 0.0 |
Polymyxin B/pharmacology | 2 | 3.0 |
Verapamil/pharmacology | 2 | 2.0 |
Lymphocytes/*immunology | 13 | 3.0 |
Monocytes/immunology | 2 | 0.0 |
Neutrophils/immunology | 3 | 1.0 |
*Protein-Serine-Threonine Kinases | 2 | 0.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Antigens/immunology | 3 | 2.0 |
*Cell Migration Inhibition | 11 | 28.0 |
Leukocytes/*immunology | 16 | 11.0 |
Skin Tests | 10 | 5.0 |
Lymphocytes/immunology | 7 | 1.0 |
Radiation Monitoring/*methods | 2 | 50.0 |
Immunity, Cellular/drug effects | 3 | 5.0 |
Leukocyte Migration-Inhibitory Factors/*pharmacology | 2 | 100.0 |
Antibody-Dependent Cell Cytotoxicity/drug effects | 2 | 11.0 |
Killer Cells, Natural/drug effects/immunology | 2 | 6.0 |
Leukocyte Migration-Inhibitory Factors/biosynthesis | 19 | 79.0 |
Heat | 8 | 1.0 |
Immunoglobulin G/biosynthesis | 2 | 1.0 |
*Lymphocyte Activation | 8 | 0.0 |
Leukocytes/immunology | 8 | 6.0 |
Granulocytes/immunology | 3 | 5.0 |
Autoantibodies/*analysis | 3 | 1.0 |
Tuberculin/immunology | 9 | 15.0 |
Dose-Response Relationship, Immunologic | 7 | 1.0 |
Lithium | 2 | 33.0 |
Radiotherapy, High-Energy | 2 | 16.0 |
*Lithium | 2 | 66.0 |
Antigens, Fungal/immunology | 2 | 9.0 |
Candida/immunology | 2 | 16.0 |
Candida albicans/immunology | 3 | 6.0 |
Antigens, Viral/immunology | 3 | 2.0 |
Immunologic Memory | 2 | 0.0 |
Chromatography, Affinity | 4 | 0.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Leukocyte Migration-Inhibitory Factors/*immunology | 3 | 100.0 |
Multiple Myeloma/*immunology | 2 | 5.0 |
Absorption | 3 | 2.0 |
Cyclosporins/*pharmacology | 2 | 5.0 |
Cytomegalovirus/*immunology | 2 | 3.0 |
Simplexvirus/*immunology | 2 | 5.0 |
Antibodies, Monoclonal/diagnostic use | 2 | 0.0 |
Lymphocytes/*physiology | 2 | 2.0 |
Breast Neoplasms/*immunology | 2 | 3.0 |
Monocytes/*immunology | 2 | 0.0 |
Dinoprostone | 4 | 5.0 |
Prostaglandins/*physiology | 2 | 8.0 |
Prostaglandins E/pharmacology | 3 | 11.0 |
*Immunity, Cellular | 5 | 3.0 |
Lymphocyte Activation/*drug effects | 4 | 1.0 |
Fetal Blood/immunology | 3 | 4.0 |
*Infant, Newborn | 2 | 4.0 |
Staphylococcus aureus/immunology | 2 | 1.0 |
Lymphokines/*immunology | 3 | 9.0 |
Lymphokines/*biosynthesis/immunology | 2 | 28.0 |
T-Lymphocytes/classification/*immunology | 2 | 3.0 |
Leukocyte Migration-Inhibitory Factors/*analysis | 4 | 100.0 |
Monokines | 2 | 11.0 |
Streptodornase and Streptokinase/pharmacology | 2 | 100.0 |
Leukocytes/drug effects | 3 | 14.0 |
Puromycin/pharmacology | 4 | 14.0 |
Hodgkin Disease/*immunology | 2 | 7.0 |
Hypersensitivity, Delayed | 2 | 3.0 |
Macrophages/immunology | 3 | 1.0 |
Mercaptoethanol/pharmacology | 2 | 6.0 |
Lung Neoplasms/immunology | 2 | 14.0 |
Acetylglucosamine/pharmacology | 2 | 20.0 |
Blood Preservation | 2 | 2.0 |
Edetic Acid/pharmacology | 2 | 1.0 |
*Immunologic Techniques | 2 | 6.0 |
*Immediate-Early Proteins | 2 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 2 | 0.0 |
Antigens | 2 | 2.0 |
Chymotrypsin/pharmacology | 2 | 10.0 |
Isoflurophate/pharmacology | 7 | 29.0 |
Neutrophils | 3 | 4.0 |
Radioallergosorbent Test | 2 | 4.0 |
Arthritis, Juvenile Rheumatoid/immunology | 2 | 28.0 |
Phenylmethylsulfonyl Fluoride/pharmacology | 6 | 37.0 |
Lymphocytes/drug effects | 2 | 2.0 |
Concanavalin A/*pharmacology | 3 | 11.0 |
Fucose/pharmacology | 2 | 33.0 |
Lactoglobulins/immunology | 2 | 33.0 |
Tosylarginine Methyl Ester/pharmacology | 2 | 100.0 |
Immunologic Techniques | 2 | 0.0 |
Acne Vulgaris/*immunology | 2 | 40.0 |
Macrophage Migration-Inhibitory Factors/biosynthesis | 3 | 27.0 |
Macrophage Migration-Inhibitory Factors/blood | 2 | 66.0 |
Sepharose | 2 | 3.0 |
*Lymphocyte Cooperation | 2 | 7.0 |
Lymphocytes/*metabolism | 3 | 1.0 |
Monocytes/drug effects/immunology | 2 | 5.0 |
Phosphorus/chemistry | 2 | 100.0 |
B-Lymphocytes/*immunology | 3 | 0.0 |
Macrophage Migration-Inhibitory Factors/*biosynthesis | 7 | 35.0 |
Immune Tolerance | 2 | 0.0 |
Cyclic GMP/*pharmacology | 2 | 28.0 |
Hydrolysis | 2 | 0.0 |
Neutrophils/metabolism | 2 | 1.0 |
Lymphocytes/*immunology/metabolism | 3 | 13.0 |
Calcium | 3 | 10.0 |
Electrophoresis, Disc | 2 | 8.0 |
Lymphocytes/drug effects/*metabolism | 2 | 8.0 |
Levamisole/*pharmacology | 2 | 25.0 |
Lymphocytes/*drug effects/metabolism | 2 | 6.0 |
Escherichia coli/immunology | 2 | 2.0 |
Macrophage Migration-Inhibitory Factors/metabolism | 2 | 40.0 |
Bucladesine/pharmacology | 2 | 1.0 |
Cyclic AMP/*pharmacology | 2 | 3.0 |
Lectins/pharmacology | 4 | 10.0 |
*Macrophage Migration-Inhibitory Factors | 3 | 60.0 |
Esterases/antagonists & inhibitors | 2 | 50.0 |
Lymphocytes/secretion | 2 | 40.0 |
Macrophage Migration-Inhibitory Factors/*antagonists & inhibitors | 2 | 50.0 |
Trypsin Inhibitors/pharmacology | 2 | 15.0 |
Phenylmethylsulfonyl Fluoride/*pharmacology | 3 | 100.0 |
Sulfones/*pharmacology | 3 | 30.0 |
Stromal Cells/drug effects/metabolism | 2 | 11.0 |
*Luminescent Measurements | 2 | 10.0 |
*Radiation Monitoring | 2 | 100.0 |
Aerospace Medicine | 2 | 8.0 |
Spectrophotometry | 2 | 1.0 |
Thermoluminescent Dosimetry/*methods/statistics & numerical data | 4 | 100.0 |
Brachytherapy/methods | 2 | 50.0 |
Thermoluminescent Dosimetry/*standards | 2 | 100.0 |
